Phoslo: Advanced Phosphate Control for Renal Health
| Product dosage: 667mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.41 | $48.19 (0%) | 🛒 Add to cart |
| 30 | $1.74 | $72.29 $52.21 (28%) | 🛒 Add to cart |
| 60 | $1.07 | $144.57 $64.25 (56%) | 🛒 Add to cart |
| 90 | $0.85 | $216.86 $76.30 (65%) | 🛒 Add to cart |
| 120 | $0.74 | $289.14 $88.35 (69%) | 🛒 Add to cart |
| 180 | $0.62 | $433.71 $112.44 (74%) | 🛒 Add to cart |
| 270 | $0.61 | $650.57 $164.65 (75%) | 🛒 Add to cart |
| 360 | $0.61
Best per pill | $867.43 $217.86 (75%) | 🛒 Add to cart |
Synonyms | |||
Phoslo (calcium acetate) is a prescription phosphate binder specifically formulated for the management of hyperphosphatemia in patients with end-stage renal disease. By effectively reducing serum phosphate levels, it plays a critical role in mitigating the risk of serious metabolic complications, including secondary hyperparathyroidism and vascular calcification. Its targeted mechanism offers nephrologists and patients a reliable tool in the ongoing management of chronic kidney disease.
Features
- Active ingredient: Calcium acetate (667 mg per tablet)
- Formulation: Oral tablet, film-coated for ease of administration
- Mechanism: Binds dietary phosphate in the intestine, forming insoluble calcium phosphate complexes
- Prescription-only medication, requiring healthcare supervision
- Available in easy-to-swallow tablet form with clear dosing demarcations
Benefits
- Effectively lowers serum phosphate levels, reducing the risk of hyperphosphatemia-related complications
- Helps prevent or slow the progression of renal osteodystrophy and vascular calcification
- Supports overall bone mineral metabolism in dialysis patients
- May reduce the need for more invasive interventions like parathyroidectomy
- Contributes to improved long-term cardiovascular outcomes in CKD patients
- Integrates seamlessly into existing renal dietary and medication regimens
Common use
Phoslo is indicated for the control of hyperphosphatemia in patients with end-stage renal disease, particularly those undergoing dialysis. It is commonly prescribed as part of a comprehensive renal management plan that includes dietary phosphate restriction and regular monitoring of calcium-phosphate product. The medication is typically initiated when serum phosphate levels exceed target ranges despite dietary modifications, and is used continuously to maintain phosphate homeostasis.
Dosage and direction
The initial dosage of Phoslo is typically 2 tablets with each meal, adjusted gradually based on serum phosphate levels and tolerance. Tablets should be swallowed whole with water and taken with meals or immediately following food intake to maximize phosphate-binding efficacy. Dosage titration should occur in 1-tablet increments per meal under medical supervision, with regular monitoring of serum calcium and phosphate levels. The maximum recommended daily dose is generally 12 tablets, though individual patient requirements may vary based on dietary phosphate intake and dialysis adequacy.
Precautions
Patients should have regular monitoring of serum calcium and phosphate levels, typically every 2-4 weeks during dosage adjustment and every 1-3 months during maintenance therapy. Caution is advised in patients with hypercalcemia, hypophosphatemia, or those taking digitalis preparations. Patients should maintain adequate hydration and report any symptoms of hypercalcemia such as nausea, vomiting, anorexia, or constipation. Periodic assessment of parathyroid hormone levels is recommended to ensure comprehensive bone mineral management.
Contraindications
Phoslo is contraindicated in patients with hypercalcemia (serum calcium >10.5 mg/dL), known hypersensitivity to calcium acetate or any component of the formulation, and in patients with low serum phosphate levels. It should not be used in patients with acute pancreatitis or in those with calcium-containing renal calculi without careful risk-benefit assessment. Concomitant use with other calcium supplements or calcium-based phosphate binders is generally contraindicated.
Possible side effects
Common side effects may include hypercalcemia (particularly with excessive dosing), nausea, vomiting, loss of appetite, and constipation. Less frequently, patients may experience dry mouth, increased thirst, or abdominal discomfort. Serious adverse effects requiring immediate medical attention include severe hypercalcemia (serum calcium >12 mg/dL), which may manifest as confusion, lethargy, coma, or cardiac arrhythmias. Long-term use may contribute to ectopic calcification in vulnerable patients.
Drug interaction
Phoslo may decrease the absorption of tetracycline antibiotics, quinolones, iron preparations, and thyroid medications when administered concurrently. Patients should separate administration of these medications by at least 2 hours before or 4 hours after Phoslo dosing. Concurrent use with vitamin D analogues may increase the risk of hypercalcemia. Caution is advised when administering with thiazide diuretics, which may decrease calcium excretion. Digitalis toxicity may be potentiated by hypercalcemia.
Missed dose
If a dose is missed, the patient should take it as soon as remembered with food, unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed administration. Consistent dosing with meals is important for optimal phosphate control, so patients should strive to maintain regular administration patterns.
Overdose
Overdose may lead to severe hypercalcemia, manifested by nausea, vomiting, anorexia, constipation, dry mouth, thirst, polyuria, lethargy, hypercalciuria, and metastatic calcification. In severe cases, confusion, delirium, stupor, coma, and cardiac arrhythmias may occur. Treatment involves discontinuation of Phoslo, hydration with saline diuresis, and monitoring of electrolyte levels. In severe cases, hemodialysis against a low-calcium bath and administration of calcitonin may be necessary.
Storage
Store at room temperature (20-25°C or 68-77°F) in a dry place protected from moisture and light. Keep the container tightly closed and out of reach of children. Do not use if the packaging is damaged or if tablets show signs of deterioration. Avoid storage in bathrooms or other humid environments. Proper disposal of expired medication should follow local regulations for pharmaceutical waste.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Treatment decisions should be made by qualified healthcare professionals based on individual patient circumstances. Patients should not alter their dosage or treatment regimen without consulting their nephrologist. The prescribing information provided here may not include all possible uses, directions, precautions, or interactions.
Reviews
Clinical studies demonstrate that Phoslo effectively reduces serum phosphate levels to target ranges in approximately 60-70% of dialysis patients when used as directed. Nephrologists report satisfactory phosphate control with appropriate dosing adjustments, though individual response varies. Some patients note gastrointestinal tolerability concerns, particularly during initial therapy, though these often resolve with continued use. Long-term users appreciate the established safety profile and predictable efficacy when combined with dietary compliance.